Innoviva, Inc. Files 8-K on Financials

Ticker: INVA · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1080014

Innoviva, INC. 8-K Filing Summary
FieldDetail
CompanyInnoviva, INC. (INVA)
Form Type8-K
Filed DateFeb 26, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k, pharmaceuticals

TL;DR

Innoviva dropped its 8-K on Feb 26, 2025, detailing financial results. Check it out.

AI Summary

Innoviva, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's fiscal year ending on December 31st. Innoviva, Inc. is incorporated in Delaware and is part of the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides crucial updates on Innoviva's financial performance and condition, which is essential for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial information is detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated February 26, 2025.

In which state is Innoviva, Inc. incorporated?

Innoviva, Inc. is incorporated in Delaware.

What is Innoviva, Inc.'s Standard Industrial Classification code and industry?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the business and mailing address for Innoviva, Inc.?

The business and mailing address is 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding Innoviva, Inc. (INVA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing